Metsera Inc. (NASDAQ:MTSR - Get Free Report) dropped 8.7% during trading on Thursday . The company traded as low as $39.40 and last traded at $39.91. Approximately 135,550 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 899,470 shares. The stock had previously closed at $43.73.
Analysts Set New Price Targets
MTSR has been the topic of a number of recent research reports. Wells Fargo & Company initiated coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Guggenheim boosted their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $55.00.
Check Out Our Latest Analysis on MTSR
Metsera Stock Up 1.3%
The company has a 50-day moving average price of $29.73.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.
Hedge Funds Weigh In On Metsera
Several large investors have recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in Metsera in the 1st quarter valued at approximately $76,000. New York State Common Retirement Fund bought a new stake in shares of Metsera in the 1st quarter valued at approximately $131,000. Corebridge Financial Inc. bought a new stake in shares of Metsera in the 1st quarter valued at approximately $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Metsera in the 1st quarter valued at approximately $248,000. Finally, MetLife Investment Management LLC bought a new stake in shares of Metsera in the 1st quarter valued at approximately $254,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
